COMMUNIQUÉS West-GlobeNewswire

SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
04/12/2025
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio , a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea , a leading global contract research [...]
Microbix Announces Initiation of Normal Course Issuer Bid
04/12/2025
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ) (“Microbix” or the “Company”), a [...]
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding [...]
Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025
04/12/2025
Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 Atavistik Bio’s [...]
2025 Cannabis Holiday Gift Guide Highlights Canada’s Most Popular Cannabis Products for the Holiday Season
04/12/2025
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired [...]
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
04/12/2025
ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported [...]
RadioMedix and Thor Medical enter supply agreement for thorium-228
04/12/2025
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical- [...]
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
04/12/2025
Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its [...]
Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026
04/12/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors [...]
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
04/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
04/12/2025
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment [...]
Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity
04/12/2025
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling [...]
Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
04/12/2025
San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003 , the company’s intravenous (IV) Deciparticle ™ [...]
Bestselling Author and Entrepreneur Dr. Reza Zahedi Expands into U.S. Market, Aiming to Build a Leading Real Estate and Media Portfolio
04/12/2025
Leadtainment founder and USA Today bestselling author announces bold U.S. expansion strategy, aiming to build a multi-million-dollar portfolio and deepen ties with key brokers, investors, and media partners. Photo [...]
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
04/12/2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early [...]
Mesoblast Participation at Piper Sandler Conference
04/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37 [...]
Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
04/12/2025
Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair [...]
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
04/12/2025
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 [...]

Pages